

**Amendments to the Claims:**

The following Listing of the Claims replaces all prior versions and all prior listings of the claims in the present application:

Listing of the Claims

1. (Currently Amended) A method of treating neurodegenerative disease in a mammal comprising the step of introducing a therapeutic effective amount of a chaperone preparation into the neurological system of the mammal.
2. (Canceled)
3. (Previously Presented) The method of claim 1, wherein the introducing step includes directly injecting the chaperone into the mammal.
4. (Withdrawn) A method for screening for a test compound for chaperone-like activity for the treatment of neurodegenerative diseases comprising the steps of:  
  
introducing the test compound into transfected cells in tissue culture, wherein such transfected cells produce protein aggregate; and  
  
measuring the quantity of protein aggregate, wherein a test compound which decreases the quantity of protein aggregate as compared to control cells has chaperone activity.
5. (Withdrawn) A method for screening for a test compound for chaperone-like activity for the treatment of neurodegenerative diseases comprising the steps of:  
  
introducing the test compound into an animal which models neurodegenerative disease;  
  
allowing said animal to develop; and  
  
subsequently measuring the quantity of aggregates in said animal wherein decreased aggregate formation over control animals indicates chaperone-like activity.

6. (Currently Amended) A method of treating neurodegenerative disease in a mammal comprising the step of introducing a therapeutically effective amount of a compound preparation into said mammal wherein said compound increases the effective concentration of a chaperone in the neurological system.
7. (Withdrawn) A method of treating neurodegenerative disease in a mammal comprising the step of introducing a therapeutically effective amount of a compound into said mammal wherein said compound increases the effective concentration or enhances the activity of a proteasome in the neurological system.
8. (Withdrawn) A method for screening for a test compound which increases proteasome activity for the treatment of neurodegenerative diseases comprising the steps of:
  - introducing the test compound into transfected cells in tissue culture, wherein such transfected cells produce protein aggregate; and
  - measuring the quantity of protein aggregate, wherein a test compound which decreases the quantity of protein aggregate is selected.
9. (Withdrawn) A method for screening for a test compound which increases proteasome activity for the treatment of neurodegenerative diseases comprising the steps of:
  - introducing the test compound into an animal which models neurodegenerative disease;
  - allowing said animal to develop; and
  - subsequently measuring the quantity of aggregates in said animal wherein a compound which shows decreased aggregate formation over control animals is selected.
10. (Withdrawn) Transgenic mice capable of overexpression of HDJ-2.
11. (Withdrawn) A method of identifying a compound for the treatment of a neurodegenerative disorder, wherein said compound has chaperone activity, comprising the steps of:

obtaining a compound suspected of having said activity; and

determining whether said compound has said activity.

12. (Canceled)

13. (Withdrawn) As a composition of matter, the compound obtained by the method of claim 11.

14. (Withdrawn) A pharmacologically acceptable composition comprising:

the compound obtained by the method of claim 11; and

a pharmaceutical carrier.

15. (Withdrawn) A method of screening for a compound for the treatment of a neurodegenerative disorder, comprising the steps of:

introducing a test compound into transfected cells in tissue culture, wherein said transfected cells produce protein aggregate; and

measuring the quantity of protein aggregate in said cells, wherein a test compound which decreases the quantity of protein aggregate as compared to control cells is considered the compound for the treatment of said neurodegenerative disorder.

16. (Canceled)

17. (Withdrawn) As a composition of matter, the compound obtained by the method of claim 15.

18. (Withdrawn) A pharmacologically acceptable composition comprising:

the compound obtained by the method of claim 15; and

a pharmaceutical carrier.

19. (Canceled)

20. (Withdrawn) A method of screening for a compound which suppresses ataxin-1 aggregation comprising the steps of:

introducing a test compound into transfected cells in tissue culture, wherein said transfected cells produce protein aggregate; and

measuring the quantity of protein aggregate in said cells, wherein a test compound which decreases the quantity of protein aggregate as compared to control cells is considered the compound which suppresses ataxin-1 aggregation.

21. (Canceled herein)

22. (Withdrawn) As a composition of matter, the compound obtained by the method of claim 20.

23. (Withdrawn) A pharmacologically acceptable composition comprising:

the compound obtained by the method of claim 20; and

a pharmaceutical carrier.

24. (Currently Amended) A method of treating a patient with a neurodegenerative disorder, comprising the steps of:

preparing a therapeutically effective amount of a chaperone compound which suppresses ataxin-1 aggregation ~~compound obtained by the method of claim 20~~; and

administering said therapeutically effective compound to said patient.

25. (Currently Amended) A method of treating a neurodegenerative disease in a mammal comprising the step of introducing a therapeutically effective amount of a compound preparation which suppresses ataxin-1 aggregation into the neurological system of the mammal.